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Objective: To assess expert consensus on barriers and facilitators for long-acting injectable 
antipsychotic (LAI) use and provide clinical recommendations on issues where clinical evidence 
is lacking, including identifying appropriate clinical situations for LAI use.
Methods: A 50-question survey comprising 916 response options was distributed to 42 research 
experts and high prescribers with extensive LAI experience. Respondents rated options on 
relative appropriateness/importance using a 9-point scale. Consensus was determined using 
chi-square test of score distributions. Mean (standard deviation) ratings were calculated. 
Responses to 29 questions (577 options) relating to appropriate patients and clinical scenarios 
for LAI use are reported.
Results: Recommendations aligned with research on risk factors for nonadherence and poor 
outcomes for patients with schizophrenia/schizoaffective or bipolar disorder. Findings suggested, 
contrary to general practice patterns, that LAI use may be appropriate earlier in the disease course 
and in younger patients. Results for bipolar disorder were similar to those for schizophrenia 
but with less consensus. Numerous facilitators of LAI prescribing were considered important, 
particularly that LAIs may reduce relapses and improve outcomes.
Conclusion: Findings support wider use of LAIs in patients with schizophrenia/schizoaffective 
and bipolar disorders beyond the setting of poor adherence and earlier use in the disease course.
Keywords: expert consensus, schizophrenia, schizoaffective disorder, bipolar disorder, 
long-acting injectable antipsychotics
Introduction
Long-acting injectable antipsychotics (LAIs) were first introduced for the treatment of 
schizophrenia more than 50 years ago, although they have remained largely underuti-
lized despite more recent availability of second-generation LAIs (SGAs).1–4 Although 
their potential clinical utility is well recognized, only 15%–28% of eligible patients with 
schizophrenia in the USA receive an LAI.3 LAIs may support adherence to maintenance 
treatment by simplifying medication regimens.1,5–7 Although some data show compa-
rable outcomes between oral antipsychotics and LAIs,8,9 several randomized controlled 
trials (RCTs) in patients with schizophrenia demonstrated a significant delay and 
reduction in relapse with LAIs compared with oral antipsychotics,10–12 particularly in 
patients with early-phase or first-episode schizophrenia.11,12 Furthermore, meta-analyses 
of mirror-image studies13 and cohort studies,14 which may include more real-world 
patients than RCTs,15 have demonstrated a lower risk of all-cause discontinuation and 
frequency of hospitalizations with LAIs versus oral antipsychotics.
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A recent expert consensus guideline from France recom-
mended LAI SGAs as first-line treatment early in schizo-
phrenia (ie, following the first psychotic episode) and for 
any patient when antipsychotic maintenance treatment is 
indicated.16 This differs from the American Psychiatric 
Association’s (APA) Practice Guideline for the Treatment 
of Patients With Schizophrenia, last updated in 2004, which 
recommended LAIs only for recurrent relapses due to non-
adherence or in patients who prefer an LAI.17 For patients 
with bipolar I disorder, the 2013 Canadian Network for Mood 
and Anxiety Treatments guidelines recommended SGA LAI 
risperidone as a first-line maintenance option.18,19 It is not 
clear how newer LAIs should be incorporated or considered 
in the context of existing guidelines that place LAIs as most 
appropriate for a relatively narrow subgroup of patients with 
schizophrenia/schizoaffective or bipolar disorder.
Antipsychotic nonadherence rates in schizophrenia are 
high; estimates as high as .50% have been reported.20,21 
Poor adherence with oral medication has been cited as a 
primary modifiable reason for poor outcomes22 and for 
prescribing LAIs.23,24 It has been shown that physicians fre-
quently underestimate poor adherence,25,26 and this finding, 
combined with the belief that LAIs should be reserved for 
nonadherent patients,16 may contribute to the underuse of 
LAIs. Negative clinician attitudes and concerns about patient 
acceptance may also contribute to the underprescribing of 
LAIs.4,24,27–30
The low rate of LAI prescribing may also stem from lack 
of available literature on the appropriate role of these agents. 
Indeed, currently available clinical trial evidence is insuf-
ficient to support treatment decisions in several key areas, 
such as selecting appropriate patients to receive LAIs, using 
treatment history as an indicator for use of LAIs, determin-
ing efficacy in patients with a recent-onset versus chronic 
mental illness, and managing adverse effects. Identifying 
potential barriers that limit the use of LAIs and potential 
facilitators that would make a healthcare provider more likely 
to consider using an LAI is important for clinical decision 
making. The expert consensus survey methodology provides 
an opportunity to develop clinical recommendations where 
evidence is lacking or when steps to support clinical decision 
making cannot be feasibly identified by RCTs.31
aim of the study
This expert consensus survey was conducted to fill gaps 
in literature and establish recommendations concerning 
appropriate use of LAIs in patients with schizophrenia/
schizoaffective or bipolar disorder.
Methods
This expert consensus survey evaluated the relative appropri-
ateness of LAI use for a variety of patient characteristics and 
clinical scenarios as well as optimal prescribing practices for 
initiation and continuation/maintenance treatment with LAIs. 
The survey was administered online via SurveyMonkey® 
(San Mateo, CA, USA) between April and November 2016 
to experts in the USA and contained 50 questions (total 
of 916 response options) to elicit respondents’ opinions 
and practices regarding LAI prescribing for patients with 
schizophrenia/schizoaffective and bipolar disorders. Aligned 
with the patient assessment and clinical decision-making 
process, the survey was organized into 3 overarching and 
sequential sections: 1) identifying patients, 2) initiation 
of therapy, and 3) maintenance treatment (Figure S1). 
Responses to 29 questions, comprising 577 response options, 
relating to appropriate patients and clinical scenarios for use 
of LAIs are reported here.
Survey respondents used a 9-point scale adapted from 
the RAND method32 to rate predefined options, with some 
questions including a write-in or comments option. The rat-
ing scale ranged from 1 to 9, with 1 representing extremely 
inappropriate or not important at all and 9 representing 
extremely appropriate or extremely important. In completing 
the survey, respondents were asked to draw on their personal 
clinical experience treating patients with schizophrenia/
schizoaffective and bipolar disorders and their knowledge 
of research and/or published literature. The survey took 
approximately 2.5–3 hours to complete and was distributed 
to 42 experts who were either researchers in mood and psy-
chotic disorders with expertise in LAI trials or clinicians 
with extensive expertise in the use of multiple LAI formula-
tions. Each research expert met 2 or more of the following 
criteria: published in the area of adherence or LAI use as it 
relates to patients with schizophrenia/schizoaffective disorder 
and/or bipolar disorder; principal investigator or co-principal 
investigator for studies involving LAIs for the treatment of 
schizophrenia and/or bipolar disorder; or individual with 
an advanced degree in psychology, medicine, or associ-
ated field who is responsible for the selection of treatment 
options for patients with schizophrenia/schizoaffective 
and/or bipolar disorders. Each clinician with extensive 
expertise fulfilled the following criteria (based on prescrib-
ing data): routinely prescribes LAIs in his or her practice; 
prescribes at least 2 different LAIs in his or her practice; 
holds an advanced degree in psychology, medicine, or 
associated field; and is responsible for the decision-making 
process for the selection of treatment options for patients 
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with schizophrenia/schizoaffective and/or bipolar disorders. 
Respondents received an honorarium for their participation 
in the survey and were blinded to the study sponsor. Respon-
dents were informed of the purpose of the survey and invited 
to continue by clicking a web button, which was deemed as 
confirming agreement. This study was exempt from approval 
by an institutional review board; it involved only the use of 
survey procedures, did not involve children, and the data was 
aggregated and anonymized such that none of the responses 
could be linked to any specific respondent.
statistical analysis
Presence or absence of consensus on each question was 
defined as a distribution unlikely to occur by chance using the 
chi-square test (P , 0.05) across 3 ranges of appropriateness 
(1–3, 4–6, 7–9). Consistent with expert consensus survey 
methodology,33 the mean rating with 95% confidence inter-
val (CI) was calculated for each option in a given question. 
Results were summarized graphically with a horizontal box 
representing the 95% CI for each consecutive option in a 
given question. Options that received a rating of 9 by $50% 
of respondents were marked by an asterisk and shading was 
used to indicate consensus. CIs of mean ratings were used to 
designate first-, second-, or third-line ratings (ie, items were 
first line if the bottom of the CI boundary was .6.5, second 
line if the bottom of the CI fell between 3.5 and 6.5, and third 
line [not appropriate] if the bottom of the CI was ,3.5). Tests 
of significance were not performed for most items; however, 
wider gaps between CIs generally indicate smaller P-values. 
Expert consensus related to identifying appropriate patients 
and clinical scenarios for LAI use and facilitators of and 
barriers to use of LAIs are summarized in this report.
Results
A total of 175 experts were invited to take the survey, 
42 of whom agreed to participate (24%). Of those sent the 
survey, 34 experts completed it (81%). A list of all survey 
respondents and their affiliations is provided in Table S1. 
The demographics and experience of the expert panel are 
summarized in Table 1. Most respondents were psychia-
trists and researchers with expertise in prescribing LAI 
and conducting studies using LAIs; the panel included 
7 clinicians with extensive LAI prescribing expertise (high 
prescribers). Overall, experts had a relatively high level of 
clinical experience. More than half reported spending either 
half, a majority, or all of their time in clinical practice. 
In addition, they reported spending a mean of 30% of their 
time treating or supervising the treatment of patients with 
schizophrenia/schizoaffective disorder and 25% of their time 
treating or supervising the treatment of patients with bipolar 
disorder. The first survey question asked how confident these 
experts were in assessing their patients’ adherence to oral 
medication, and most indicated they were only somewhat 
confident (45%) or not very confident (33%).
Table 1 Demographics and practice characteristics of expert 
panel
Demographic and practice experience Value
Mean (range) age, years 58 (42–82)
Male sex, n (%) 21 (62)
Mean (range) years in practice 25 (0–45)
Degree, n (%)
MD
PhD
DNP
PharmD
24 (71)
6 (18)
2 (6)
2 (6)
involved in schizophrenia, bipolar disorder, or major 
depressive disorder research (within previous 5 years), n (%)
22 (65)
Mean (range) research experience, years 22 (0–52)
NiMh/Nih research grant as principal investigator, n (%) 15 (44)
Principal investigator for an industry-sponsored grant, n (%) 20 (59)
Practice environment Value
Proportion of time spent seeing patients, n (%)
all/majority of the time 12 (36)
50% of the time 7 (21)
25% of the time 10 (29)
,10% of the time 5 (15)
Practice setting(s) where significant number of patients 
seen,a n (%)
Private practice 8 (25)
Public sector 11 (34)
academic clinical or research setting 23 (69)
Mean percentage of time (range) spent treating or 
supervising the treatment of patients, by disease
schizophrenia/schizoaffective disorder 30 (0–100)
Bipolar disorder 25 (0–75)
Major depressive disorder 24 (0–60)
Mean percentage of patients (range) with insurance 
coverage
Private insurance 30 (0–100)
Medicaid 33 (0–75)
Medicare 22 (0–70)
Uninsured 15 (0–70)
Mean percentage of patients (range) treated by age group
,18 years 10 (0–75)
18–34 years 35 (0–55)
35–65 years 41 (0–70)
.65 years 13 (0–65)
Mean percentage of patients (range) in practice currently 
receiving lai, by disease
schizophrenia/schizoaffective disorder 33 (0–100)
Bipolar disorder 11 (0–40)
Note: asome experts may have provided .1 response.
Abbreviations: lai, long-acting injectable antipsychotic; NiMh/Nih, National 
institute of Mental health/National institutes of health.
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selecting appropriate patients
Experts rated the appropriateness of initiating an LAI in 
patients with schizophrenia/schizoaffective or bipolar dis-
order based on a variety of demographic and clinical char-
acteristics. Options that received a ranking of 9 by .50% 
on experts were considered extremely appropriate. Options 
rated first line were considered very or usually appropriate, 
second line as somewhat appropriate, and third line as inap-
propriate. For a patient with schizophrenia/schizoaffective 
disorder who has been treated with an antipsychotic medi-
cation for $2 years, regardless of whether the person is 
considered generally adherent or not; the experts gave first-
line rankings (very or usually appropriate) to considering 
an LAI in the following clinical situations: poor insight into 
illness and need for treatment, homeless or unstable hous-
ing situation, history of multiple (.2) hospitalizations for 
psychotic relapses, history of violence to others, living alone, 
history of a suicide attempt, substance use disorder, promi-
nent psychotic symptoms, young adult (age 18–25 years), 
and cognitive impairment. As can be seen in Figure 1, rec-
ommendations for a patient with bipolar disorder who has 
been treated with medication for $2 years and is considered 
generally adherent to treatment were generally the same as 
for schizophrenia but with only 2 items receiving first-line 
consensus: history of multiple hospitalizations and homeless 
or unstable housing situation. If the adherence of the longer-
term patient with bipolar disorder is questionable, the experts 
also gave first-line ratings to a history of violence and poor 
insight.
Results were similar when experts were asked about 
patients with schizophrenia/schizoaffective or bipolar 
disorder of recent onset. For a patient with schizophrenia/
schizoaffective disorder with onset during the previous 
2 years, a history of multiple (.2) hospitalizations for 
psychotic relapses, homeless or unstable housing situation, 
and history of violence to others were rated by $50% of 
experts as extremely appropriate (rating = 9) factors for 
LAI use. Poor insight into illness and need for treatment, 
Figure 1 expert consensus on selecting appropriate patients with schizophrenia/schizoaffective and bipolar disorders for lai treatment.
Notes: rating scale: 1 = extremely inappropriate, 2–3 = usually inappropriate, 4–6 = sometimes appropriate, 7–8 = usually appropriate, 9 = extremely appropriate. horizontal 
bars represent cis. *Options that received highest ranking by $50% of respondents. Open bars indicate no consensus; shaded bars indicate consensus (dark shading = first 
line; medium shading = second line; light shading = third line). Colors of the survey questions correlate to the colors in the figure.
Abbreviation: lai, long-acting injectable antipsychotic.
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living alone, prominent psychotic symptoms, and history of 
suicide attempt also received first-line ratings.
Recommendations for LAI use in a patient with bipolar 
disorder of recent onset (,2 years) were similar to those for 
schizophrenia/schizoaffective disorder, but only homeless or 
unstable housing situation, history of violence to others, and 
history of multiple (.2) hospitalizations for bipolar relapses 
received consensus ratings as usually appropriate.
When considering treatment history, factors considered 
by consensus to be extremely appropriate for LAI use in 
schizophrenia/schizoaffective disorder were similar regard-
less of adherence status (Table 2). Experts agreed that patients 
who have a preference for LAIs, have done well on an LAI 
in the past, or have family conflict related to oral medication 
nonadherence are all extremely appropriate candidates for 
LAI treatment. In patients with questionable adherence, 
frequently missing clinic appointments was an additional 
scenario in which LAI use was considered to be extremely 
appropriate (Table 2).
When considering treatment history in patients with bipolar 
disorder who were treated with medication for $2 years, 
consensus was reached on 2 situations as extremely appro-
priate for LAI use (Table 3). Similar to schizophrenia/
schizoaffective disorder, $50% of experts agreed that 
LAIs are extremely appropriate for patients with bipolar 
disorder who prefer an LAI, regardless of treatment adher-
ence. In addition, experts agreed it is extremely appropriate 
(rated 9 by $50% of the experts) to use an LAI for a patient 
Table 2 expert consensus on selecting patients with schizophrenia/schizoaffective disorder who are appropriate for lai treatment 
based on treatment history
Rating Patient with schizophrenia/schizoaffective disorder treated with antipsychotic medication for $2 years (mean [SD] 
ratinga)
Assumed treatment adherence Questionable treatment adherence
First line Prefers LAI (8.8 [0.6]) Prefers LAI (8.8 [0.5])
Has done well on LAI in the past (8.4 [0.9]) Has done well on LAI in the past (8.3 [1.3])
Conflict in family related to adherence to oral 
medication (8.4 [0.9])
Conflict in family related to adherence to oral 
medication (8.3 [1.1])
Frequently misses clinic appointments (8.1 [1.1]) Frequently misses clinic appointments (8.3 [1.0])
Family/care partner does not support antipsychotic treatment 
regimen (7.5 [2.0])
Family/care partner does not support antipsychotic treatment 
regimen (7.6 [1.8])
Patient with whom i have a good therapeutic alliance (7.1 [1.7]) Patient with whom i have a good therapeutic alliance (7.6 [1.5])
has done well on oral antipsychotic medications in the past but 
has never been treated with an lai (7.5 [1.3])
concomitant maintenance treatment with other psychotropic 
medications (eg, mood-stabilizing agents, antidepressants) 
(7.5 [1.8])
Positive symptoms (hallucinations, delusions) have responded 
well to oral antipsychotic medications, but patient continues 
to have negative symptoms or cognitive symptoms/impairment 
(7.2 [1.6])
high second 
lineb
concomitant maintenance treatment with other psychotropic 
medications (eg, mood-stabilizing agents, antidepressants) 
(6.6 [1.7])
Positive symptoms (hallucinations, delusions) have not 
responded to previous trials of oral antipsychotic medications 
(7.2 [2.2])
Patient with whom i do not have a strong therapeutic alliance 
(6.6 [2.1])
Patient with whom i do not have a strong therapeutic alliance 
(7.1 [1.9])
Positive symptoms (hallucinations, delusions) have responded well 
to oral antipsychotic medications, but patient continues to have 
negative symptoms or cognitive symptoms/impairment (6.5 [2.0])
Patient being treated with an antipsychotic indicated for 
treatment-resistant schizophrenia but is still experiencing 
positive symptoms (6.5 [2.4])
Positive symptoms (hallucinations, delusions) have not responded 
to previous trials of oral antipsychotic medications (6.5 [2.3])
history of refusing treatment with lai (6.5 [2.0])
has done well on oral antipsychotic medications in the past but 
has never been treated with an lai (6.5 [2.0])
Patient being treated with an antipsychotic indicated for 
treatment-resistant schizophrenia but is still experiencing positive 
symptoms (6.2 [2.4])
history of refusing treatment with lai (6.1 [2.1])
Notes: arating scale: 1 = extremely inappropriate, 2–3 = usually inappropriate, 4–6 = sometimes appropriate, 7–8 = usually appropriate, 9 = extremely appropriate; bold 
indicates an option rated 9 by $50% of the experts. bhigh second-line options are those for which the upper value of the ci is $6.5, the boundary for first line.
Abbreviation: lai, long-acting injectable antipsychotic.
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with bipolar disorder when adherence is questionable and 
an LAI has worked well in the past (Table 3). Other factors 
considered usually appropriate for LAI use in patients with 
bipolar disorder treated with medication for $2 years who 
are assumed to be generally adherent to treatment were 
those with a history of suboptimal adherence to medica-
tions, having previously done well on an LAI, and frequently 
missing clinic appointments. In those with questionable 
adherence, experts agreed that LAIs are usually appropriate 
when adherence to medications has been suboptimal in the 
past, clinic appointments are frequently missed, prior lithium 
or anticonvulsant mood stabilizer treatment has failed, 
relapses are predominantly manic, or when the therapeutic 
alliance is good.
Facilitators of and barriers to prescribing 
long-acting injectable antipsychotics
Experts were also asked to rank the importance of potential 
barriers to healthcare providers prescribing LAIs. Barriers 
were divided into 3 different categories: patient related, 
system related, or medication related. Although none of the 
barriers received first-line ratings (indicating that none were 
viewed as barriers that consistently stood out as being most 
important), a number of barriers did receive high second-line 
ratings. For potential patient-related barriers, high second-
line consensus ratings were given for a patient who does not 
want an injection and/or is afraid of needles, perceives LAIs 
as coercive or punitive, and whose family does not support 
use of LAIs. When asked about potential system-related 
barriers, LAIs not being adequately covered by insurance 
plans, inability to bill for injection and office visit on the same 
day, and LAI being too costly were all factors that received 
high second-line consensus ratings. Finally, medication-
related barriers receiving high second-line consensus rat-
ings were the patient having had a previous bad experience 
with an LAI and the existence of treatment guidelines that 
suggest reserving LAIs for patients with multiple relapses, 
nonadherence, or previous LAI experience. Lack of clarity 
concerning the appropriate LAI dosage received a consensus 
second-line rating.
In addition to ranking potential LAI barriers, respondents 
were also asked to write in what they considered to be the 
top 3 barriers limiting use of LAIs. The most important barri-
ers were all potentially modifiable factors and included drug 
cost, insurance reimbursement, negative patient perceptions 
of LAIs, stigma associated with injections, lack of knowledge 
of or experience with LAIs, and limited staff/infrastructure 
(Table S2).
After rating potential barriers to LAI use, the experts 
ranked the relative importance of a list of factors, beliefs, 
and perceptions as potential facilitators to LAI prescribing 
in patients with schizophrenia, schizoaffective disorder, 
Table 3 expert consensus on selecting patients with bipolar disorder who are appropriate for lai treatment based on treatment history
Rating Patient with established diagnosis of bipolar disorder and treated with medication for $2 years (mean [SD] 
ratinga)
Assumed treatment adherence Questionable treatment adherence
First line Prefers LAI (8.4 [0.9]) Prefers LAI (8.6 [0.7])
history of suboptimal adherence to medications (7.6 [1.2]) Has done well on LAI in the past (8.3 [1.0])
has done well on lai in the past (7.5 [1.5]) history of suboptimal adherence to medications (7.9 [1.3])
Frequently misses clinic appointments (7.3 [1.7]) Frequently misses clinic appointments (7.4 [1.5])
has failed to respond to lithium or anticonvulsant 
mood-stabilizing medications (7.1 [1.8])
Predominant history of manic relapse (7.1 [1.8])
Patient with whom i have a good therapeutic alliance (7.1 [1.8])
high second 
lineb
has shown only partial response to lithium or 
anticonvulsant mood-stabilizing medications (6.9 [1.5])
has shown only partial response to lithium or anticonvulsant 
mood-stabilizing medications (7.0 [1.7])
has failed to respond to lithium or anticonvulsant 
mood-stabilizing medications (6.8 [1.9])
Patient with whom i do not have a strong therapeutic alliance 
(6.9 [1.8])
Patient with whom i have a good therapeutic alliance 
(6.8 [1.9])
concomitant treatment with other mood-stabilizing agents or 
antidepressants (6.7 [2.0])
Patient with whom i do not have a strong therapeutic 
alliance (6.6 [1.8])
has done well on oral antipsychotic medications in the past but 
has never been treated with an lai (6.6 [2.0])
Predominant history of manic relapse (6.5 [1.7])
has done well on oral antipsychotic medications in the 
past but has never been treated with an lai (6.0 [2.3])
Notes: arating scale: 1 = extremely inappropriate, 2–3 = usually inappropriate, 4–6 = sometimes appropriate, 7–8 = usually appropriate, 9 = extremely appropriate; bold 
indicates an option rated 9 by $50% of the experts. bhigh second-line options are those for which the upper value of the ci is $6.5, the boundary for first line.
Abbreviation: lai, long-acting injectable antipsychotic.
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or bipolar disorder. All options, with the exception of LAIs 
being less expensive than oral medication, were considered to 
be important facilitators of LAI use. More than half of experts 
agreed that reducing the risk of relapse and hospitalization 
and improving patient outcomes were extremely important 
facilitators of LAI use (rated 9 by $50% of experts). A com-
plete list of facilitators rated as first line and high second line 
is provided in Table 4.
Discussion
Findings from this survey on patient selection for LAIs 
generally align with research on risk factors for nonadherence 
and poor outcomes in people with severe mental disorders.23,34 
Consistent with current APA guidelines in schizophrenia,16 
experts considered LAI antipsychotics an appropriate option 
for individuals with known nonadherence or questionable 
adherence. Beyond nonadherence, experts positioned LAIs 
as an appropriate treatment for patients with more severe 
illness or limited social supports or for those at a particularly 
high risk of relapse.
There was more consensus on what constitutes the appro-
priate use of LAIs for schizophrenia/schizoaffective disorder 
than for bipolar disorder. This tendency likely reflects a 
general lack of published data and experience to inform 
evidence-based treatment decisions on LAI use in patients 
with bipolar disorder. Overall, recommendations were similar 
for patients with fairly recent disease onset (,2 years) versus 
those diagnosed and receiving medication for $2 years, 
suggesting that experts may support broader use of LAIs 
beyond the current APA guidance.17 Although experts rated 
a greater number of scenarios as usually appropriate for LAI 
use when patients have questionable adherence, a number 
of additional clinical scenarios were also considered usually 
appropriate in patients with assumed adherence. This finding 
suggests that experts may recommend LAIs as a strategy to 
prevent relapse due to factors other than adherence alone or 
that they consider using LAIs preemptively, assuming that 
nonadherence is likely in the future.
When experts ranked potential barriers to LAI prescrib-
ing by healthcare providers, no barriers were consistently 
rated as being most important. This may indicate that most 
barriers were seen as surmountable. Consensus was achieved 
on several high second-line factors related to other types of 
barriers such as fear of needles (patient-related barrier), LAIs 
not being adequately covered by insurance plans (system-
related barrier), and the appropriate dosage not being clear 
(medication-related barrier). Write-in answers on the 3 most 
important barriers to LAI use in patients with schizophrenia/
schizoaffective or bipolar disorder were medication cost/
lack of insurance reimbursement, negative perceptions of 
and stigma associated with LAIs, and lack of knowledge 
and experience concerning how to use and dose LAIs. 
Table 4 First- and high second-line expert ratings on the importance of potential facilitators for consideration of lai use in a patient 
with schizophrenia/schizoaffective or bipolar disorder
Rating Factors, beliefs, or perceptions about LAIs by healthcare providers that would facilitate 
consideration of an LAI (mean [SD] ratinga)
First line Reduced risk of relapse and hospitalization (8.3 [1.0])
Improved patient outcomes (8.2 [1.1])
No need for patient to make a daily decision to take medication or remember to take medication daily (8.1 [0.9])
reduced symptoms because of continuous medication coverage (7.8 [1.6])
reduced burden and increased satisfaction for families (7.6 [1.3])
ability for the clinician to identify nonadherence immediately and intervene as soon as it is detected (7.6 [1.7])
Better symptom control for patient who might abuse substances and reduce or stop medication (7.6 [1.4])
improved patient and physician satisfaction (7.4 [1.3])
No or minimal concern about lai being taken incorrectly or misused because staff are administering (reduced 
risk of unintentional or deliberate overdose) (7.2 [1.3])
high second 
lineb
Ability for the clinician to discriminate inadequate response due to lack of efficacy versus poor response due to 
adherence problems (7.1 [2.0])
No need for patient to refill prescription for oral medication (6.9 [2.1])
No concern about patient losing medication (6.9 [1.7])
ensures regular contact between patient and treatment team (6.7 [2.0])
More time to focus on nonmedication-related issues rather than adherence issues in clinical sessions (6.7 [1.9])
reduced stigma associated with having to take daily psychiatric medication (6.7 [1.8])
Patients who travel do not need to carry medication with them (6.4 [2.0])
less variation in peak-to-trough antipsychotic blood level with lower risk of peak-level side effects (6.3 [1.8])
Notes: arating scale: 1 = not important at all, 2–3 = not very important, 4–6 = somewhat important, 7–8 = important, 9 = extremely important; bold indicates an option 
rated 9 by $50% of the experts. bhigh second-line options are those for which the upper value of the ci is $6.5, the boundary for first line.
Abbreviation: lai, long-acting injectable antipsychotic.
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These recommendations are consistent with the observations 
in a previous systematic literature review, which addition-
ally reported regional differences in LAI prescribing based 
on acceptance of community-based systems of care.35 The 
experts agreed on numerous factors that may facilitate LAI 
use, with more than half of the experts rating reduced risk 
of relapse/hospitalization and improved patient outcomes as 
being extremely important facilitators. This is consistent with 
meta-analytic findings from mirror image and cohort studies 
of LAIs versus oral antipsychotics13,14 as well as several RCTs 
in patients with recently diagnosed schizophrenia.10–12
Although the 2004 APA schizophrenia guidelines 
generally recommended LAIs for patients who prefer an LAI 
or for those who are nonadherent,16 newer guidelines recom-
mend LAI SGAs as first-line treatment for schizophrenia and 
as maintenance treatment for bipolar disorder.16,18,36 Although 
disadvantages of LAIs include longer time to achieve steady 
state and less flexibility with dose adjustments,1 LAIs may 
also simplify the treatment regimen and reduce patient 
medication-taking burden.1,5,37 Advantages of LAIs beyond 
potentially improving adherence include being able to obtain 
an accurate assessment of dosing and regularity of treatment 
actually received, potentially strengthening the therapeutic 
alliance,4 and slower antipsychotic clearance, which may 
decrease the risk of clinical deterioration if a patient abruptly 
discontinues treatment.1,5,37
Although expert consensus guidelines in France 
have recommended early use of LAIs for patients with 
schizophrenia,16 European surveys show that clinicians 
still tend to reserve LAIs for patients later in the disease 
course.38–40 Results from this survey suggest that a shift may 
be occurring in the USA, with experts and high prescribers 
viewing LAIs as also being appropriate early in the course of 
schizophrenia. Earlier use of LAIs may potentially limit the 
progressive decline in functioning associated with disease 
recurrence.41–43 Two prospective randomized trials in first-
episode patients with schizophrenia found that frontal lobe 
white matter volume changes differed between patients 
receiving the LAI risperidone than in those receiving oral 
risperidone;42,43 in the first of these studies, greater white 
matter volume in the LAI group was associated with faster 
reaction times during cognitive performance testing.42 The 
expert consensus survey reported here also suggests that 
LAIs are usually appropriate for early-stage schizophrenia, 
when patients have a lot to gain (and to lose) psychosocially 
and functionally. Clinically, however, LAIs do not seem 
to be used preferentially in younger patients. For example, 
Barnes et al found no age or sex differences between 
patients who were prescribed LAIs and those prescribed oral 
antipsychotics in a UK study.27
There are a number of limitations to this survey, including 
low overall response rate and a sample size that was relatively 
small and insufficient to compare the responses of research 
experts versus high prescribers. Additionally, the duration of 
time needed to complete the survey may introduce the risk 
of inconsistent responses. Further, LAIs were considered 
as a group and individual differences between LAIs were 
not emphasized when seeking expert opinion. However, the 
completion rate for this survey was high overall, and meth-
odological strengths included the blinded format (survey 
respondents were not provided information on funding 
source) and US national representation of experts. Moreover, 
the methodology has previously been used to provide guid-
ance for treatment decisions in patients with schizophrenia44,45 
and bipolar disorder.46
Results from this expert consensus suggest that more 
research is needed to better understand how LAIs should be 
positioned in the treatment armamentarium for patients with 
schizophrenia/schizoaffective or bipolar disorder, including 
how barriers to LAI use should be addressed and how facilita-
tors of use may be best utilized. The rest of the survey results 
are presented in an accompanying paper.47
In conclusion, where clinical trial data are insufficient, 
the expert consensus survey method provides quantitative 
data that can be used to develop clinical recommendations 
based on expert opinion.31 In addition to providing recom-
mendations on the use of LAIs in patients with schizophrenia/
schizoaffective and bipolar disorders, these survey findings 
may also help guide future research in this area.
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Supplementary materials
Figure S1 Organization of survey.
Note: To simulate the treatment decision process, questions were organized into 3 main areas: identifying patients, initiation of therapy, and maintenance treatment.
Abbreviation: lai, long-acting injectable antipsychotic.
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Table S1 survey respondents
anissa abi-Dargham, MD, stony Brook University
rimal Bera, MD, University of california, irvine
Kelly Bliss, DNP, Mental Bliss, Pllc
William carpenter, MD, Maryland Psychiatric research center, University of Maryland school of Medicine
leslie citrome, MD, MPh, New York Medical college
christoph correll, MD, The Zucker hillside hospital and hofstra Northwell school of Medicine
colin Depp, PhD, University of california, san Diego
Nassir ghaemi, MD, Tufts Medical center
radhika gollapudy, MD
Philip harvey, PhD, University of Miami
rona hu, MD, stanford University
rakesh Jain, MD, MPh, Private Practice, austin, TX, Usa
anita Kablinger, MD, cPi, carilion clinic, Virgnia Tech carilion school of Medicine
John Kane, MD, The Zucker hillside hospital
samuel Keith, MD, University of New Mexico
Paul Maguire, MD, community Partners of strafford county
stephen Marder, MD, University of california, los angeles
Michael Measom, MD, New roads/aD Psychotherapy/Volunteers of america
David Miklowitz, PhD, University of california, los angeles, semel institute
Frederick Mittleman, MD, cODac-health recovery Wellness
ricky Mofsen, DO, evolution research group
Mary Moller, DNP, MSN, Pacific Lutheran University
Diana Perkins, MD, University of North carolina
stacey rawls, MD, Private Practice, rocky Mount, Nc 
Martha sajatovic, MD, case Western reserve University school of Medicine
stephen saklad, PharmD, BcPP, The University of Texas at austin, college of Pharmacy, Pharmacotherapy Division
Nina r. schooler, PhD, sUNY Downstate Medical center
aimee schwartz, MD, Terros health
asim shah, MD, Baylor college of Medicine
Tracey skale, MD, greater cincinnati Behavioral
roger sommi, PharmD, BcPP, University of Missouri-Kansas city schools of Pharmacy and Medicine
georgia stevens, PhD, Director, P.a.l. associates: Partners in aging & long-Term caregiving
Michael Thase, MD, University of Pennsylvania
Dawn Velligan, PhD, University of Texas health science center at san antonio
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Table S2 General summary of expert opinion on the top barriers to the use of LAIs in the field
Barriers to the use of LAIs Experts who listed barrier as ranking in the 
top 3 to limit the use of LAIs, n (N = 31)
cost/not on formulary/not reimbursed by insurance 14
Negative perception/prescriber bias/stigma associated with injections as coercive, 
punitive, taking away patient autonomy/fear of impact on therapeutic alliance
14
lack of knowledge/experience with lais and how to dose them 11
lack of infrastructure and staff to use lais/time constraints/concern about it 
being more work to prescribe and provide lais
11
Perceptions about the types of patients for whom lais are appropriate (eg, only 
patients who are nonadherent, who have had multiple relapses, who are seen as 
the “worst of the worst,” with schizophrenia but not bipolar disorder)
9
Patient refusal/fear/dislike of injections 8
concern about inability to adjust dosage/discontinue medication immediately as 
needed, concern about persistence of potential side effects
6
Problems presenting/explaining lais to patients 5
availability of only a limited number of lais with FDa indications 3
lack of family support 3
Believing patients will reject lais but not asking patients themselves 2
concern about patients not returning for injections 2
concern about pain at injection site 1
Overestimation of patients’ level of adherence 1
Patient having to come into the office biweekly or monthly for injections 1
lack of awareness of the importance of adherence 1
Abbreviations: FDa, Us Food and Drug administration; lai, long-acting injectable antipsychotic.
